Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC Birch PROBE Study
2008-006292-77Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- Feb 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Sublivac Birch in allergic rhinoconjunctivitis (ARC), allergic conjunctivitis (AC) and atopic disease (2 arms), sponsored by HAL Allergy Group. Primary endpoint: Change in titrated nasal provocation test (TNPT) response. Started Feb 2009; status: completed.
02
Drugs
Sublivac Birch
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic conjunctivitis (AC)atopic disease
Beyond the preview
Go deeper on 2008-006292-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006292-77.